The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).

MedStar author(s):
Citation: European Journal of Surgical Oncology. 44(12):1942-1948, 2018 12.PMID: 30075978Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Colorectal Neoplasms/pa [Pathology] | *Cytoreduction Surgical Procedures/mt [Methods] | *Hyperthermia, Induced/mt [Methods] | *Peritoneal Neoplasms/sc [Secondary] | *Peritoneal Neoplasms/th [Therapy] | *Practice Patterns, Physicians'/sn [Statistics & Numerical Data] | Combined Modality Therapy | Humans | Internet | Surveys and Questionnaires | Treatment OutcomeYear: 2018Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:2002-2007ISSN:
  • 0748-7983
Name of journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyAbstract: BACKGROUND: At present, selected patients with resectable colorectal peritoneal metastases (CRC-PM) are increasingly treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study was to investigate the current worldwide practice.CONCLUSION: This international survey demonstrates that CRS and HIPEC is now performed on a large scale for CRC-PM patients. Variation in treatment may result in heterogeneity in surgical and oncological outcomes, emphasising the necessity to reach consensus on several issues of this comprehensive procedure. Future initiatives directed at achieving an international consensus statement are needed.Copyright (c) 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.METHODS: HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning their personal expertise and current hospital and countrywide practice.RESULTS: It is estimated that currently more than 3800 patients with CRC-PM (synchronous and metachronous) are annually treated with CRS and HIPEC in 430 centers. Integration of CRS and HIPEC in national guidelines varies, resulting in large treatment disparities between countries. Amongst the experts, there was general agreement on issues related to indication, surgical technique and follow up but less on systemic chemotherapy or proactive strategies.All authors: Bushati M, Cashin PH, Ceelen W, de Hingh IHJT, Deraco M, Dube P, Glehen O, Gonzalez-Moreno S, Lehmann K, Li Y, Moran B, Morris DL, Piso P, Quadros CA, Rovers KP, Somashekhar SP, Sommariva A, Spiliotis J, Sugarbaker PH, Teo MCC, Verwaal VJ, Yonemura YFiscal year: FY2019Digital Object Identifier: Date added to catalog: 2018-08-16
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 30075978 Available 30075978

Available online from MWHC library: 1995 - present, Available in print through MWHC library:2002-2007

BACKGROUND: At present, selected patients with resectable colorectal peritoneal metastases (CRC-PM) are increasingly treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study was to investigate the current worldwide practice.

CONCLUSION: This international survey demonstrates that CRS and HIPEC is now performed on a large scale for CRC-PM patients. Variation in treatment may result in heterogeneity in surgical and oncological outcomes, emphasising the necessity to reach consensus on several issues of this comprehensive procedure. Future initiatives directed at achieving an international consensus statement are needed.

Copyright (c) 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

METHODS: HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning their personal expertise and current hospital and countrywide practice.

RESULTS: It is estimated that currently more than 3800 patients with CRC-PM (synchronous and metachronous) are annually treated with CRS and HIPEC in 430 centers. Integration of CRS and HIPEC in national guidelines varies, resulting in large treatment disparities between countries. Amongst the experts, there was general agreement on issues related to indication, surgical technique and follow up but less on systemic chemotherapy or proactive strategies.

English

Powered by Koha